Maan Pratibha, Gautam Rohit, Vasudevan Sudharsan, Menon Geetha R, Arora Amit, Nair Abilash, Jabbar Puthiyaveettil Khadar, Arora Taruna
Indian Council of Medical Research (ICMR) Headquarters, New Delhi 110029, India.
Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi 110001, India.
Pharmaceuticals (Basel). 2025 May 2;18(5):680. doi: 10.3390/ph18050680.
Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age. Treatment or management of this syndrome includes several pharmacological and non-pharmacological treatment approaches for different manifestations of the disease that vary with the patient's age, symptoms, requirements, and geographical location. This systematic review aims to conduct a comprehensive and evidence-based analysis of the various available treatment options and identify knowledge gaps in PCOS management in India. A comprehensive search was conducted in PubMed, Scopus, and Embase databases from January 2010 till February 2024. We included randomized control trials (RCTs) using any pharmacological drugs (e.g., insulin sensitizers, anti-androgens, anti-obesity drugs, oral contraceptive pills, ovulation induction drugs, etc.) or non-pharmacological intervention (e.g., yoga, diet, herbal supplements, etc.) with Indian PCOS patients for improving common manifestations of PCOS and written in the English language. Studies were screened by two authors independently in a two-level process. Data extraction was also performed by two authors. Risk of bias was performed using the RoB 2 Tool. Subgroup analysis and meta-analysis were performed using the RevMan tool. Thirty RCTs on pharmacological and eight on non-pharmacological interventions were included in the study. However, all the RCTs were so heterogeneous in terms of intervention used, subject recruited, and outcomes measured that meta-analysis was possible for only three subgroups (metformin vs. inositol, metformin vs. metformin+ inositol, and letrozole vs. clomiphene citrate), with only two or three studies per analysis. Most studies were single-centric and small-sized and had a high risk of bias, limiting their generalizability. This systematic review synthesized existing research and evaluated the effectiveness and safety of existing treatments. Limitations and gaps in the current research were identified, which may inform future research for better understanding and management of PCOS in the Indian context.
多囊卵巢综合征(PCOS)是一种在育龄女性中普遍存在的内分泌紊乱疾病。该综合征的治疗或管理包括针对疾病不同表现的多种药物和非药物治疗方法,这些方法会因患者年龄、症状、需求和地理位置而有所不同。本系统评价旨在对各种可用的治疗选择进行全面且基于证据的分析,并找出印度PCOS管理方面的知识空白。我们于2010年1月至2024年2月在PubMed、Scopus和Embase数据库中进行了全面检索。我们纳入了使用任何药物(如胰岛素增敏剂、抗雄激素药物、抗肥胖药物、口服避孕药、促排卵药物等)或非药物干预(如瑜伽、饮食、草药补充剂等)的随机对照试验(RCT),这些试验针对印度PCOS患者以改善PCOS的常见表现,且研究报告为英文撰写。研究由两位作者独立进行两级筛选。数据提取也由两位作者完成。使用RoB 2工具进行偏倚风险评估。使用RevMan工具进行亚组分析和荟萃分析。该研究纳入了30项关于药物治疗的RCT和8项关于非药物干预的RCT。然而,所有这些RCT在干预措施、招募对象和测量结果方面差异极大,以至于仅对三个亚组(二甲双胍与肌醇、二甲双胍与二甲双胍 + 肌醇、来曲唑与枸橼酸氯米芬)进行了荟萃分析,每个分析仅有两到三项研究。大多数研究为单中心、小样本,且存在较高的偏倚风险,限制了其可推广性。本系统评价综合了现有研究,并评估了现有治疗方法的有效性和安全性。明确了当前研究中的局限性和空白,这可能为未来在印度背景下更好地理解和管理PCOS的研究提供参考。